Atlas Trials

Inovio Pharmaceuticals

31 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Inovio Pharmaceuticals

RecordFirmDate
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers (NCT05430958)Inovio Pharmaceuticals2022-10-01
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (NCT04588428)Inovio Pharmaceuticals2021-06-21
Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (NCT04093076)Inovio Pharmaceuticals2021-01-27
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (NCT04642638)Inovio Pharmaceuticals2020-11-30
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) (NCT04398433)Inovio Pharmaceuticals2020-10-07
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (NCT04336410)Inovio Pharmaceuticals2020-04-03
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (NCT03721978)Inovio Pharmaceuticals2019-02-28
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (NCT03491683)Inovio Pharmaceuticals2018-05-31
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (NCT03502785)Inovio Pharmaceuticals2018-05-24
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 (NCT03499795)Inovio Pharmaceuticals2018-05-15

Track Inovio Pharmaceuticals automatically

Every clearance here is in the API, with alerts when new ones post.